All Stories

  1. Towards Automatic Detection of Misinformation in Online Medical Videos
  2. Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination
  3. Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube
  4. Twitter response to the 2018 US Preventive Services Task Force guidelines on prostate cancer screening
  5. Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer
  6. Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance
  7. Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media
  8. Social media coverage of scientific articles immediately after publication predicts subsequent citations: #SoMe_Impact Score (Preprint)
  9. Crowdfunding for prostate cancer and breast cancer
  10. Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015
  11. A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men
  12. Public online reporting from a nationwide population-based clinical prostate cancer register
  13. Prostate cancer and social media
  14. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer
  15. Biomarkers in active surveillance
  16. Informational needs during active surveillance for prostate cancer: A qualitative study
  17. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions
  18. Educational intervention in prostate cancer
  19. Twitter Activity Associated With U.S. News and World Report Reputation Scores for Urology Departments
  20. Management of Prostate Cancer in Sweden
  21. Re: The Prostate Health Index Adds Predictive Value to Multi-parametric MRI in Detecting Significant Prostate Cancers in a Repeat Biopsy Population
  22. Genomic testing for localized prostate cancer
  23. An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy
  24. Biomarkers for Prostate Biopsy and Risk Stratification of Patients with Newly Diagnosed Prostate Cancer
  25. Shift from protocol-based to personalized medicine in active surveillance: beginning of a new era
  26. Tweet this: how advocacy for breast and prostate cancers stacks up on social media
  27. Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
  28. Newsworthiness vs scientific impact: are the most highly cited urology papers the most widely disseminated in the media?
  29. Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer
  30. The role of prostate cancer biomarkers in undiagnosed men
  31. When is a Negative Prostate Biopsy Really Negative? Repeat Biopsies in Detection and Active Surveillance
  32. Novel use of Twitter to disseminate and evaluate adherence to clinical guidelines by the European Association of Urology
  33. Editorial Comment
  34. Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy
  35. Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study
  36. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer
  37. Curating a Digital Identity: What Urologists Need to Know About Social Media
  38. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment
  39. Qualitative study on decision-making by prostate cancer physicians during active surveillance
  40. An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care
  41. Activity, content, contributors, and influencers of the twitter discussion on urologic oncology
  42. Beyond prostate-specific antigen
  43. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy
  44. Complications After Systematic, Random, and Image-guided Prostate Biopsy
  45. Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort
  46. Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools
  47. Immediate versus delayed prostatectomy: Nationwide population-based study*
  48. Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma
  49. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy
  50. Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012
  51. Small bowel obstruction and abdominal pain after robotic versus open radical prostatectomy
  52. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States
  53. Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference
  54. Prostate biopsy decisions: one-size-fits-all approach with total PSA is out and a multivariable approach with the Prostate Health Index is in
  55. Postoperative mortality 90 days after robot-assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide population-based study
  56. Screening for familial and hereditary prostate cancer
  57. The Prostate Health Index
  58. Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study
  59. Genomic Predictors of Outcome in Prostate Cancer
  60. Novel survey disseminated through Twitter supports its utility for networking, disseminating research, advocacy, clinical practice and other professional goals
  61. Controversies in management of high-risk prostate and bladder cancer
  62. Prostate cancer: Growth of AS in the USA signals reduction in overtreatment
  63. Editorial Comment
  64. Impact of Early Diagnosis of Prostate Cancer on Survival Outcomes
  65. Prostate Cancer on the Web—Expedient Tool for Patients’ Decision-Making?
  66. Is Magnetic Resonance Imaging–Transrectal Ultrasound Fusion Biopsy Ready for “Prime Time”?
  67. Future-proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?
  68. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer
  69. Population-based study of long-term functional outcomes after prostate cancer treatment
  70. Editorial Comment
  71. Editorial Comment
  72. Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification
  73. Twitter response to the United States Preventive Services Task Force recommendations against screening with prostate‐specific antigen
  74. Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations
  75. Upper limit of cancer extent on biopsy defining very low-risk prostate cancer
  76. Predicting prostate biopsy results—PCA3 versus phi
  77. Five-year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer
  78. Social media makes global urology meetings truly global
  79. Editorial Comment
  80. Editorial Comment
  81. Editorial Comment
  82. Editorial Comment
  83. Editorial Comment
  84. Nationwide Population Based Study of Infections after Transrectal Ultrasound Guided Prostate Biopsy
  85. A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease
  86. Guideline of guidelines: prostate cancer screening
  87. Editorial Comment
  88. Genetically adjusted prostate‐specific antigen values may prevent delayed biopsies in African‐American men
  89. Engaging responsibly with social media: the BJUI guidelines
  90. Overdiagnosis and Overtreatment of Prostate Cancer
  91. Use of social media in urology: data from the American Urological Association (AUA)
  92. Prostate Cancer Risk Alleles are Associated with Prostate Cancer Volume and Prostate Size
  93. Editorial Commentary
  94. Early Detection of Prostate Cancer
  95. “To Measure Is To Know. If You Cannot Measure It, You Cannot Improve It”: Statistical Modeling Cannot Compensate for Unmeasured Bias
  96. Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories
  97. Editorial Comment
  98. Population Based Study of Predictors of Adverse Pathology among Candidates for Active Surveillance with Gleason 6 Prostate Cancer
  99. The Melbourne Consensus Statement on the early detection of prostate cancer
  100. Editorial Comment
  101. The Prostate Health Index: a new test for the detection of prostate cancer
  102. The age old question: who benefits from prostate cancer treatment?
  103. National Trends in the Utilization of Partial Nephrectomy Before and After the Establishment of AUA Guidelines for the Management of Renal Masses
  104. Systematic Review of Complications of Prostate Biopsy
  105. Editorial Comment
  106. Population Based Study of Use and Determinants of Active Surveillance and Watchful Waiting for Low and Intermediate Risk Prostate Cancer
  107. Bacteriuria and antibiotic resistance in catheter urine specimens following radical prostatectomy
  108. Prostate Health Index—improving screening in men with family history
  109. Does Delaying Prostate Cancer Treatment Miss the Window of Curability?
  110. Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage Inappropriate Prostate Cancer Imaging
  111. Editorial Comment
  112. Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers
  113. Prostate Health Index (PHI): Golden Bullet or Just Another Prostate Cancer Marker?
  114. Personalized Prostate Specific Antigen Testing Using Genetic Variants May Reduce Unnecessary Prostate Biopsies
  115. Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration
  116. The Utility of Prostate-Specific Antigen Screening and Prostate Cancer Treatment in Elderly Patients
  117. 2066 FEWER HOSPITAL ADMISSIONS FOR INFECTION AFTER GENTAMICIN AND CEFTRIAXONE PROSTATE BIOPSY PROPHYLAXIS
  118. 1925 PSA VELOCITY PER PROSTATE VOLUME: A TOOL FOR PROSTATE CANCER DIAGNOSIS
  119. 661 POPULATION-BASED STUDY OF UTILIZATION AND DETERMINANTS OF ACTIVE SURVEILLANCE AND WATCHFUL WAITING FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER
  120. 2063 CHARACTERISTICS AND PREDICTORS OF PROSTATE NEEDLE BIOPSY COMPLIANCE
  121. Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility
  122. Is Repeat Prostate Biopsy Associated with a Greater Risk of Hospitalization? Data from SEER-Medicare
  123. Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?
  124. Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study
  125. The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary
  126. PSA Dynamics
  127. Association of [−2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer
  128. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam
  129. External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series
  130. Novel Technique for Fragment Removal After Percutaneous Management of Large-volume Neobladder Calculi
  131. Infectious Complications and Hospital Admissions After Prostate Biopsy in a European Randomized Trial
  132. Prostate-specific antigen screening can be beneficial to younger and at-risk men
  133. Use of Baseline Prostate-Specific Antigen Measurements to Personalize Prostate Cancer Screening
  134. 2215 NOMOGRAM WITH “PSA ACCELERATION” PREDICTING HIGH GRADE PROSTATE CANCER
  135. Prostate cancer: Modeling the outcomes of prostate cancer screening
  136. Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk Calculators
  137. Editorial Comment
  138. Environmental exposures and prostate cancer
  139. AN EXAMINATION OF THE DYNAMIC CHANGES IN PROSTATE-SPECIFIC ANTIGEN OCCURRING IN A POPULATION-BASED COHORT OF MEN OVER TIME
  140. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer
  141. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease
  142. Early Detection, Diagnosis, and Staging of Prostate Cancer
  143. Baseline Prostate-Specific Antigen Testing at a Young Age
  144. Prostate-specific antigen (PSA) should drive doing prostate biopsies
  145. Re: Randomised Prostate Cancer Screening Trial: 20 Year Follow-up
  146. Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis
  147. The relationship between prostate volume and prostate-specific antigen variability: data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program
  148. Complications After Prostate Biopsy: Data From SEER-Medicare
  149. Infection after Transrectal Ultrasonography-Guided Prostate Biopsy: Increased Relative Risks after Recent International Travel or Antibiotic Use
  150. Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level
  151. Editorial Comment
  152. Prostate Cancer Risk Alleles and Their Associations With Other Malignancies
  153. Re: An Empirical Evaluation of Guidelines on Prostate-Specific Antigen Velocity in Prostate Cancer Detection
  154. Editorial Comment
  155. Editorial Comment
  156. Can We Stop Prostate Specific Antigen Testing 10 Years After Radical Prostatectomy?
  157. GENETIC BASIS FOR PROSTATE CANCER
  158. Use of Empiric Antibiotics in the Setting of an Increased Prostate Specific Antigen
  159. PREDICTION OF OUTCOMES AFTER RADICAL PROSTATECTOMY IN PATIENTS DIAGNOSED WITH PROSTATE CANCER OF BIOPSY GLEASON SCORE ≥ 8 VIA CONTEMPORARY MULTI(≥12)-CORE PROSTATE BIOPSY
  160. Delay of Surgery in Men With Low Risk Prostate Cancer
  161. A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range
  162. Should prostate-specific antigen velocity be abandoned?
  163. Germline Sequence Variants and Prostate-Specific Antigen Interpretation
  164. Editorial Comment
  165. Reply
  166. Distribution of PSA Velocity by Total PSA Levels: Data From the Baltimore Longitudinal Study of Aging
  167. What Is the True Number Needed to Screen and Treat to Save a Life With Prostate-Specific Antigen Testing?
  168. Significance of preoperative PSA velocity in men with low serum PSA and normal DRE
  169. Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease
  170. Reply
  171. Diabetes mellitus and prostate cancer risk
  172. Correlation Between Serum Prostate-specific Antigen and Cancer Volume in Prostate Glands of Different Sizes
  173. The Vanishing Prostate Cancer Phenomenon
  174. What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?
  175. Genetic Prostate Cancer Risk Assessment: Common Variants in 9 Genomic Regions are Associated With Cumulative Risk
  176. Prostate Specific Antigen at the Initial Diagnosis of Metastasis to Bone in Patients After Radical Prostatectomy
  177. Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer
  178. Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program
  179. Is statin use associated with prostate cancer aggressiveness?
  180. Prostate-specific antigen screening: pro
  181. Preoperative Prostate Specific Antigen Doubling Time is Not a Useful Predictor of Biochemical Progression After Radical Prostatectomy
  182. Utility of the Riskindicator model in screening
  183. 1722 USE OF PSA DERIVATIVES TO DETERMINE THE NEED FOR REPEAT BIOPSY
  184. Regional Variation in Total Cost per Radical Prostatectomy in the Healthcare Cost and Utilization Project Nationwide Inpatient Sample Database
  185. [-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening Study
  186. Benign prostate glands at the bladder neck margin in robotic vs open radical prostatectomy
  187. Prostate Biopsy: A Risk-Benefit Analysis
  188. The Case for Open Radical Prostatectomy
  189. Treatment Outcomes of Radical Prostatectomy in Potential Candidates for 3 Published Active Surveillance Protocols
  190. Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program
  191. Bone mineral content and prostate cancer risk: data from the Baltimore Longitudinal Study of Aging
  192. PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer
  193. Is Prostate-Specific Antigen Surveillance Necessary in Men with Benign Prostate Pathology following Radical Cystoprostatectomy for Bladder Cancer?
  194. Can Prostate Specific Antigen Velocity Thresholds Decrease Insignificant Prostate Cancer Detection?
  195. Editorial Comment
  196. Should Prostate Specific Antigen be Adjusted for Body Mass Index? Data From the Baltimore Longitudinal Study of Aging
  197. Reducing blood loss in open radical retropubic prostatectomy with prophylactic periprostatic sutures
  198. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer
  199. Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?
  200. Tertiary Gleason Patterns and Biochemical Recurrence After Prostatectomy: Proposal for a Modified Gleason Scoring System
  201. Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging
  202. Risk Factors, Prevention and Early Detection of Prostate Cancer
  203. Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes?
  204. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease
  205. Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate Specific Antigen Level
  206. Is PSA velocity useful?
  207. Pathological Outcomes Associated With the 17q Prostate Cancer Risk Variants
  208. Characteristics of Prostate Cancers Detected at Prostate Specific Antigen Levels Less Than 2.5 ng/ml
  209. Investigation of Human Anti-mouse Antibodies as Potential Cause of Postprostatectomy PSA Elevation
  210. Prostate Specific Antigen Testing Among the Elderly—When To Stop?
  211. Biomarkers for Prostate Cancer
  212. What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels?
  213. Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA)
  214. A case of gastrointestinal stromal tumor diagnosed on prostate biopsy
  215. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer
  216. Does PCA3 Help Identify Clinically Significant Prostate Cancer?
  217. Prostate Specific Antigen Assay Standardization Bias Could Affect Clinical Decision Making
  218. Rebuttal from Authors re: Axel Heidenreich. Identification of High-Risk Prostate Cancer: Role of Prostate-Specific Antigen, PSA Doubling Time and PSA Velocity. Eur Urol 2008;54:976–7
  219. PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging
  220. Management of Distal Ureter in Laparoscopic Nephroureterectomy—A Comprehensive Review of Techniques
  221. PSA Velocity Is Associated With Gleason Score in Radical Prostatectomy Specimen: Marker for Prostate Cancer Aggressiveness
  222. Does primary androgen-deprivation therapy improve survival for localized prostate cancer?
  223. Does Prostate Growth Confound Prostate Specific Antigen Velocity? Data From the Baltimore Longitudinal Study of Aging
  224. Complications of Open Radical Retropubic Prostatectomy in Potential Candidates for Active Monitoring
  225. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis
  226. Long-Term Rates of Undetectable PSA with Initial Observation and Delayed Salvage Radiotherapy after Radical Prostatectomy
  227. Combined Prostate-specific Antigen Density and Biopsy Features to Predict “Clinically Insignificant” Prostate Cancer
  228. Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles
  229. Relationship of Prostate-Specific Antigen Velocity to Histologic Findings in a Prostate Cancer Screening Program
  230. Progression after radical prostatectomy for men in their thirties compared to older men
  231. Thoracic Complications of Urologic Laparoscopy: Correlation between Radiographic Findings and Clinical Manifestations
  232. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?
  233. Comparison of Prostate Specific Antigen Velocity in Screened Versus Referred Patients With Prostate Cancer
  234. What to Do with an Abnormal PSA Test
  235. Prostate-Specific Antigen and Prostate Cancer Screening
  236. Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only
  237. Prostate Specific Antigen Velocity in Men With Total Prostate Specific Antigen Less Than 4 ng/ml
  238. Open radical retropubic prostatectomy
  239. Prestenting Improves Ureteroscopic Stone-Free Rates
  240. Improved Stage and Grade-Specific Progression-Free Survival Rates After Radical Prostatectomy in the PSA Era
  241. Pathological Features After Radical Prostatectomy in Potential Candidates for Active Monitoring
  242. Under Diagnosis and Over Diagnosis of Prostate Cancer
  243. Early versus delayed intervention for prostate cancer: the case for early intervention
  244. Intermediate-Term Potency, Continence, and Survival Outcomes of Radical Prostatectomy for Clinically High-Risk or Locally Advanced Prostate Cancer
  245. Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting from Different Assays for Free and Total Prostate-Specific Antigen
  246. Risk of Prostate Cancer for Young Men With a Prostate Specific Antigen Less Than Their Age Specific Median
  247. The role of high-intensity focused ultrasound in prostate cancer
  248. Prostate-specific antigen in clinical practice
  249. The Association Between Total Prostate Specific Antigen Concentration and Prostate Specific Antigen Velocity
  250. Prostate Specific Antigen Velocity Threshold for Predicting Prostate Cancer in Young Men
  251. Use of Prostate-Specific Antigen Velocity to Follow Up Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia on Prostate Biopsy
  252. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors
  253. Does Body Mass Index Affect Preoperative Prostate Specific Antigen Velocity or Pathological Outcomes After Radical Prostatectomy?
  254. Comparison of Methods for Calculating Prostate Specific Antigen Velocity
  255. Characteristics of Patients With Familial Versus Sporadic Prostate Cancer
  256. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: Early results
  257. Use of BioGlue in laparoscopic partial nephrectomy
  258. What is the prognostic impact of positive surgical margins in surgically treated prostate cancer?
  259. Lymphovascular invasion in radical prostatectomy specimens: Prediction of adverse pathologic features and biochemical progression
  260. Management of the complications of external beam radiotherapy and brachytherapy
  261. Making prostate-specific antigen testing more effective
  262. A Prospective Study of Laparoscopic Radical Nephrectomy for T1 Tumors—Is Transperitoneal, Retroperitoneal or Hand Assisted the Best Approach?
  263. Management of the complications of external beam radiotherapy and brachytherapy
  264. Pathological Characteristics of Prostate Cancer Detected Through Prostate Specific Antigen Based Screening
  265. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old
  266. The PSA Era is not Over for Prostate Cancer